PDCD1 and melanoma: For example, Andrew’s team uses melanoma models and anti-PD-1/CTLA-4 therapy to demonstrate that immune checkpoint therapy induces the translocation of specific intestinal bacteria to secondary lymphoid organs and tumors, thus activating Dendritic Cells (DCs) and triggering anti-tumor responses of T cells.